1-2 of 2
Adam Forbes
Close
Sort by
Journal Articles

High Responses Rates with Single Agent Belantamab Mafodotin in Relapsed Systemic AL Amyloidosis

Jahanzaib Khwaja, Joshua Bomsztyk, Ceri Bygrave, Adam Forbes, Senthilkumar Durairaj, Savio Fernandes, James Taylor, Pamela Paterson, Gillian Brearton, Charles Crawley, Oonagh Sheehy, Rachel Brown, Richard Soutar, Mamta Garg, Andrzej Rydzewski, Krzysztof Jamroziak, Emma Dowling, Nuno Correia, Sarah Worthington, Shameem Mahmood, Ashutosh D. Wechalekar
Journal: Blood
Blood (2023) 142 (Supplement 1): 3408.
https://doi.org/10.1182/blood-2023-182042
Published: 2023
Journal Articles

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Rakesh Popat, Ajay Nooka, MDMPH, Keith Stockerl-Goldstein, MD, Rafat Abonour, MD, Ryan Ramaekers, MD, Amit Khot, MD, Adam Forbes, MD, Cindy Lee, MD, Bradley Augustson, MBBS FRACP FRCPA, Andrew Spencer, Maria-Victoria Mateos, MD PhD, Bikramjit Chopra, PhD, Rachel Rogers, MS, Deborah A Smith, PharmD, Jacqueline Davidge, PhD, Rocio Montes de Oca, PhD, Geraldine Ferron-Brady, PhD, Anne Yeakey, MD, Mala Talekar, MD, Brandon E. Kremer, MD PhD, Ira Gupta, MD, Hang Quach, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-139332
Published: 2020